Cellectar Biosciences (CLRB) Projected to Announce Quarterly Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Cellectar Biosciences to announce earnings of ($0.5565) per share and revenue of $17.00 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). On average, analysts expect Cellectar Biosciences to post ($2.39) EPS for the current fiscal year and ($2.08) EPS for the next fiscal year.

Cellectar Biosciences Price Performance

Shares of CLRB stock traded up $0.02 on Wednesday, hitting $1.33. The stock had a trading volume of 40,562 shares, compared to its average volume of 363,719. The firm has a market capitalization of $12.57 million, a P/E ratio of -0.35 and a beta of 0.65. Cellectar Biosciences has a 1 year low of $1.12 and a 1 year high of $4.70. The company’s 50 day moving average price is $1.83 and its 200-day moving average price is $2.62.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CLRB. Brookline Capital Markets raised Cellectar Biosciences to a “strong-buy” rating in a research report on Sunday, July 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Thursday, October 15th. Finally, Wall Street Zen cut shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue.

The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.